Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Arnaud Jannin1, Alexandre Lugat2, Alexandre Escande3

  • 1Université de Lille, CNRS, Inserm, CHU de Lille, UMR9020-U1277 - CANTHER - Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers, F-59000 Lille, France; CHU de Lille, Département d'endocrinologie, de diabétologie et de métabolisme, F-59000, Lille, France.

Bulletin Du Cancer
|November 6, 2024
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

OncoMimic peptide-based immunotherapy EO2401 induces shared T cell clusters in patients with adrenal cancer.

Communications medicine·2026
Same author

[18F]F-DOPA and [18F]F-FDG PET/CT for staging advanced medullary thyroid cancer.

Annales d'endocrinologie·2026
Same author

[Cabozantinib - unresectable or metastatic well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors after at least one prior line of systemic therapy other than somatostatin analogues].

Bulletin du cancer·2026
Same author

[<sup>177</sup>Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trial.

The Lancet. Oncology·2026
Same author

Impact of the French ENDOCAN-COMETE Network on Overall Survival in Rare Adrenocortical Carcinomas.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Management of Hemodialyzed Patients Treated with Radioactive Iodine for Thyroid Cancer: How Could We Improve It? Tracks from the Lille Experience.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
This summary is machine-generated.

Anaplastic thyroid carcinoma (ATC) management has improved with molecular testing, targeted therapies, and immunotherapy. Rapid, specialized care protocols in expert centers enhance survival for this rare, aggressive cancer.

Area of Science:

  • Oncology
  • Endocrinology
  • Molecular Diagnostics

Background:

  • Anaplastic thyroid carcinoma (ATC) is a rare, aggressive thyroid cancer with historically poor prognosis and short survival.
  • Clinical presentation often involves a rapidly growing neck mass causing compressive symptoms in elderly patients.
  • Limited surgical options at diagnosis due to frequent loco-regional invasion.

Purpose of the Study:

  • To outline the latest advancements in the management of anaplastic thyroid carcinoma in 2024.
  • To highlight the impact of molecular testing, targeted therapies, and immunotherapy on patient outcomes.
  • To emphasize the importance of rapid, multidisciplinary care in expert centers.

Main Methods:

  • Urgent biopsy for diagnosis and mandatory BRAFV600E mutation testing.
Keywords:
Anaplastic thyroid carcinomaBRAF(V600E)Carcinome anaplasique de la thyroïdeDabrafenibDabrafénibImmunotherapiesImmunothérapiesTrametinibTramétinib

Related Experiment Videos

  • Expedited care coordination within specialized networks (TUTHYREF-path, ENDOCAN-TUTHYREF).
  • Multimodal treatment strategies including targeted therapy (BRAF/MEK inhibitors), chemotherapy, radiotherapy, and immunotherapy.

    • Main Results:

    • Improved survival outcomes observed with the systematic application of molecular testing and targeted therapies.
    • BRAF/MEK inhibitors demonstrate efficacy in BRAFV600E-mutated ATC.
    • Immunotherapy (PD-1/PD-L1 inhibitors) shows potential, but optimal use and biomarkers require further research.

    Conclusions:

    • Modern management of ATC integrates molecular profiling with multimodal therapies for improved outcomes.
    • Multidisciplinary expert centers and rapid diagnostic/treatment protocols are crucial for managing this aggressive cancer.
    • Further research is needed to optimize immunotherapy sequencing and identify predictive biomarkers for personalized treatment.